<DOC>
	<DOCNO>NCT02834468</DOCNO>
	<brief_summary>The project undertaken Qilu Hospital , Shandong University China . In order report efficacy safety dexamethasone combine rituximab , cyclosporin intravenous immunoglobulin management newly diagnose ITP patient .</brief_summary>
	<brief_title>DEX Combined With RTX , CSA IVIG Management Newly Diagnosed ITP Patients</brief_title>
	<detailed_description>The investigator undertake multicenter trial 100 primary ITP adult patient 5 medical center China . All participant receive dexamethasone ( give orally dose 40 mg per day 4 day ) , rituximab ( give intravenously dose 500mg ) , cyclosporin ( give orally dose 2.5-3 mg/kg per day 28 day ) intravenous immunoglobulin ( give intravenously dose 5g per month 6 month ) treatment adult newly diagnose ITP patient .</detailed_description>
	<mesh_term>Thrombocytopenia</mesh_term>
	<mesh_term>Purpura , Thrombocytopenic , Idiopathic</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Immunoglobulins , Intravenous</mesh_term>
	<mesh_term>gamma-Globulins</mesh_term>
	<mesh_term>Rho ( D ) Immune Globulin</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<criteria>1 . Meet diagnostic criterion immune thrombocytopenia . 2 . Untreated hospitalized patient , may male female , age 18 60 year . 3 . To show platelet count &lt; 30×10^9/L , bleed manifestation . 4 . Eastern Cooperative Oncology Group（ECOG）performance status ≤ 2 . 5 . Willing able sign write informed consent 1 . Received chemotherapy anticoagulant drug affect platelet count within 3 month screen visit . 2 . Received highdose steroid [ 2 ] intravenous immunoglobulin transfusion ( IVIG ) 3 week prior start study . 3 . Current HIV infection hepatitis B virus hepatitis C virus infection . Severe medical condition ( lung , hepatic renal disorder ) ITP . 4.Unstable uncontrolled disease condition relate impacting cardiac function ( e.g. , unstable angina , congestive heart failure , uncontrolled hypertension cardiac arrhythmia ) 5.Female patient nurse pregnant , may pregnant , contemplate pregnancy study period . 6.Have known diagnosis autoimmune disease , establish medical history laboratory finding positive result determination antinuclear antibody , anticardiolipin antibody , lupus anticoagulant direct Coombs test . 7.Patients deem unsuitable study investigator .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Dexamethasone</keyword>
	<keyword>Rituximab</keyword>
	<keyword>Cyclosporin</keyword>
	<keyword>Intravenous Immunoglobulin</keyword>
</DOC>